Stock Yards Bank & Trust Co. decreased its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 2.2% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 55,258 shares of the biopharmaceutical company’s stock after selling 1,233 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Bristol-Myers Squibb were worth $3,079,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Blue Chip Partners Inc. boosted its position in shares of Bristol-Myers Squibb by 0.8% during the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 17 shares during the last quarter. Keel Point LLC lifted its position in Bristol-Myers Squibb by 0.3% during the first quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 18 shares during the last quarter. Staley Capital Advisers Inc. lifted its position in Bristol-Myers Squibb by 0.3% during the first quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock valued at $379,000 after purchasing an additional 24 shares during the last quarter. Shayne & CO. LLC lifted its position in Bristol-Myers Squibb by 0.7% during the first quarter. Shayne & CO. LLC now owns 4,017 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 27 shares during the last quarter. Finally, Founders Capital Management LLC lifted its position in Bristol-Myers Squibb by 0.7% during the first quarter. Founders Capital Management LLC now owns 4,097 shares of the biopharmaceutical company’s stock valued at $223,000 after purchasing an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 68.88% of the company’s stock.

Bristol-Myers Squibb Company (NYSE:BMY) traded up 0.80% on Monday, reaching $62.98. 2,819,409 shares of the company traded hands. The stock has a 50 day moving average of $58.56 and a 200-day moving average of $55.95. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $63.47. The stock has a market capitalization of $103.28 billion, a price-to-earnings ratio of 23.00 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The company had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. During the same quarter in the prior year, the company posted $0.69 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 5.6% compared to the same quarter last year. On average, equities analysts anticipate that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be given a $0.39 dividend. The ex-dividend date of this dividend is Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.50%. Bristol-Myers Squibb’s payout ratio is currently 56.73%.

Several equities analysts have commented on the stock. BidaskClub upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, June 10th. Vetr lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 price objective for the company. in a research report on Tuesday, August 22nd. Deutsche Bank AG set a $55.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Monday, July 17th. Credit Suisse Group set a $58.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Wednesday, August 16th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Wednesday, July 12th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $62.66.

In related news, Director Theodore R. Samuels II bought 6,000 shares of the firm’s stock in a transaction on Wednesday, August 2nd. The shares were bought at an average price of $55.94 per share, with a total value of $335,640.00. Following the completion of the transaction, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Joseph C. Caldarella sold 9,340 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.

WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/09/18/stock-yards-bank-trust-co-reduces-position-in-bristol-myers-squibb-company-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.